A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma

Sonia Vallet, Nicholas R Hoyle, Robert A Kyle, Klaus Podar, Martin Pecherstorfer

Research output: Journal article (peer-reviewed)Journal article

8 Citations (Scopus)

Abstract

Multiple myeloma (MM) is characterized by bone lesions arising due to unbalanced bone remodeling. Changes in the bone formation marker amino-terminal propeptide of type I collagen (PINP) and the bone resorption marker β-CrossLaps (CTX) reflect physiologic bone turnover. Whether PINP and CTX have a role in disease progression from monoclonal gammopathy of undetermined significance (MGUS) to MM is unknown. In this cross-sectional follow-up study, 241 patients with MM or MGUS were included. Serum levels of PINP and CTX were significantly higher in MM patients compared to MGUS. Moreover, increasing concentrations of PINP and CTX were observed in those MGUS patients progressing to MM, whereas PINP and CTX levels remained unchanged in MGUS patients with stable disease. In conclusion, these data indicate a potential role of PINP and CTX as biomarkers for the progression of MGUS to MM.

Original languageEnglish
Pages (from-to)2431-2438
Number of pages8
JournalLeukemia and Lymphoma
Volume59
Issue number10
DOIs
Publication statusPublished - 3 Oct 2018

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers/blood
  • Collagen/blood
  • Cross-Sectional Studies
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Monoclonal Gammopathy of Undetermined Significance/blood
  • Multiple Myeloma/blood
  • Peptide Fragments/blood
  • Procollagen/blood

Fingerprint

Dive into the research topics of 'A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma'. Together they form a unique fingerprint.

Cite this